Open AccessEfficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer andCXCL5expression: Six case reports
Author(s) -
Apolonia Novillo,
María Gaibar,
Alicia RomeroLorca,
María Fuencisla Gilsanz,
Laura Beltrán,
Miguel Galán,
Beatriz Flores Antón,
Diego Malón,
Amália Moreno,
Ana Fernández-Santander
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i16.1979
Subject(s) - bevacizumab , colorectal cancer , medicine , oncology , chemotherapy , cxcl5 , cancer , cancer research , receptor , chemokine
In metastatic colorectal cancer (mCRC), the anti-vascular endothelial growth factor drug bevacizumab (BVZ) plus chemotherapy significantly improves progression-free survival compared to chemotherapy (CT) alone. This benefit is not, however, observed in all patients. While increased chemokine CXCL5 gene expression promoting angiogenesis has been proposed as a prognostic mCRC biomarker, few studies have examined its relationship with drug efficacy. This study sought to analyze tumor CXCL5 gene expression in six patients with different efficacy of BVZ-containing CT in terms of the tumor response to treatment.